Aimmune Therapeutics, Inc. (AIMT) EPS Estimated At $-0.79

July 14, 2018 - By Jason Grubb

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Logo

Analysts expect Aimmune Therapeutics, Inc. (NASDAQ:AIMT) to report $-0.79 EPS on August, 14.They anticipate $0.14 EPS change or 21.54 % from last quarter’s $-0.65 EPS. After having $-0.92 EPS previously, Aimmune Therapeutics, Inc.’s analysts see -14.13 % EPS growth. The stock increased 2.30% or $0.66 during the last trading session, reaching $29.34. About 312,621 shares traded. Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has risen 78.81% since July 14, 2017 and is uptrending. It has outperformed by 66.24% the S&P500.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.71 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

More news for Aimmune Therapeutics, Inc. (NASDAQ:AIMT) were recently published by: Investorplace.com, which released: “10 Top Stock Ideas to Beat the Blues” on July 06, 2018. Globenewswire.com‘s article titled: “New Research Coverage Highlights Avery Dennison, Raymond James Financial, Genuine Parts, Kimco Realty, Bristow …” and published on June 15, 2018 is yet another important article.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.